Zepbound has three approved maintenance doses rather than one, so where you stay is an actual decision. What SURMOUNT-4 found about continuing, and what maintenance is really protecting.
3Approved Zepbound maintenance doses: 5, 10 and 15 mg
25%+Of lost weight regained by most who withdrew in SURMOUNT-4
52 weeksLength of the randomised continuation phase in that trial
−19.3%Total fat mass change in the STEP 1 body composition substudy
Key takeaways
Zepbound is unusual among GLP-1 medications in having three approved maintenance doses — 5, 10 and 15 mg — rather than a single top dose.
That means the highest dose you can tolerate is not automatically the dose you should stay on. Where you maintain is a real clinical choice.
SURMOUNT-4 tested continuing versus withdrawing after 36 weeks: most who withdrew regained 25% or more of their lost weight within a year, and cardiometabolic improvements went back with it.
7.5 mg and 12.5 mg are escalation steps, not approved maintenance doses.
The maintenance failure modes are protein slipping, resistance training stopping, and food noise returning quietly — none of which the scale reports early.
Zepbound is approved for maintenance at 5 mg, 10 mg or 15 mg once weekly.
Wegovy has one maintenance dose. Zepbound has three, and that changes the conversation.
The Zepbound dose ladder. Only three of these steps are approved maintenance doses.
Dose
Role
2.5 mg
Starting dose. Adaptation, not treatment. Four weeks.
5 mg
Maintenance dose First step where staying is an option.
7.5 mg
Escalation step only.
10 mg
Maintenance dose A common landing point.
12.5 mg
Escalation step only.
15 mg
Maintenance dose Maximum approved dose.
The practical consequence: climbing to 15 mg because it is the top of the ladder is not
automatically the goal. If your result is holding at 10 mg with fewer side effects, that is a
legitimate destination rather than a compromise. The
titration schedule tool maps the steps and dates.
What the maintenance evidence shows
SURMOUNT-4 is the trial that tested staying on against coming off.
Participants took tirzepatide for 36 weeks, then 670 were randomised to 52 more weeks of
treatment or to placebo.
Among those who had achieved at least 10% weight reduction in the open-label phase, most who
withdrew regained 25% or more of the weight they had lost within the year. The post-hoc analysis
in JAMA Internal Medicine found the cardiometabolic gains reversed alongside the weight rather
than persisting on their own.
Read the way it is useful rather than the way it is discouraging: the trial is evidence that
maintenance treatment maintains, not evidence that the loss was fake. The people who continued
kept their result.
Choosing where to maintain
The question your prescriber is weighing is which of 5, 10 or 15 mg holds your result
with the fewest side effects. Things that usually feed into it:
Where the result actually held. If weight was stable for a couple of months at 10 mg,
that is data.
Side effect burden at each step. Worth knowing which dose produced which symptoms,
which is the kind of detail nobody reconstructs accurately from memory.
Food noise. If it returns reliably on day six or seven, that is information about
dose adequacy and worth reporting specifically.
Cost and supply. Real constraints. Better named than worked around silently.
What is not a good reason to move: the number being lower than someone else's. Maintenance
doses are not a ranking.
The part maintenance is actually about
Once weight has stopped falling, the job changes from losing fat to keeping the body
composition you ended up with. That is a different task and it fails quietly.
A meaningful share of weight lost in any large, rapid loss is lean tissue — in the
STEP 1 body composition substudy total fat mass fell 19.3% while the proportion of lean mass to
total body mass rose, so composition improved overall even though lean tissue was part of the
loss. Maintenance is when that becomes the thing to protect.
Two levers, and both get dropped at exactly this point:
Protein. Still hard on a suppressed appetite, and no longer urgent-feeling. Aim at a
number rather than an intention — the protein
target calculator gives you one.
Resistance training. Two sessions a week is where the evidence gets consistent.
The third failure mode is simply stopping weighing. Understandable, and it is what turns a
three-pound drift into a fifteen-pound surprise.
What to track through a transition
The useful signals move before the scale does, and none of them are things anyone
remembers accurately three weeks later. If you are changing anything about your
treatment, these four are worth writing down as they happen:
Food noise. Intrusive food thoughts, grazing urges, whether old portions have
started looking normal again. This is usually the first thing to move.
Hunger pattern. Not just how often, but whether meals still finish the feeling.
Weight trend, weekly. A seven-day average, not a daily number. Daily weights during
a transition mostly measure hydration and generate anxiety.
Dose history. Exact dates of every change, missed dose, dose stretch, side effect
and supply gap. This is the part clinicians most often ask about and patients most often
cannot answer.
The point is not to become a data project. It is that "hunger came back around week three
and I was up four pounds by week six" is a conversation that produces a plan, while "I think
it's been getting worse" is not.
Common questions
What is the maintenance dose of Zepbound?
Zepbound is approved for maintenance at 5 mg, 10 mg or 15 mg once weekly. 2.5 mg is a starting dose, and 7.5 mg and 12.5 mg are escalation steps rather than approved maintenance doses.
Do I have to go all the way to 15 mg?
No. Because Zepbound has three approved maintenance doses, staying at 5 or 10 mg is a legitimate destination if your result holds there with fewer side effects. Where you maintain is a clinical decision, not a ranking.
What happens if I stop Zepbound?
In SURMOUNT-4, most participants who withdrew after 36 weeks of tirzepatide regained 25% or more of the weight they had lost within a year, and the post-hoc analysis found cardiometabolic improvements reversed alongside it.
Is Zepbound the same as Mounjaro?
Same molecule, tirzepatide, with different licensed indications: Zepbound for weight management, Mounjaro for type 2 diabetes. Insurance coverage can differ between them for the same person.
How do I keep muscle during Zepbound maintenance?
Protein intake and resistance training are the two levers with consistent evidence. Both tend to slip once weight stops falling and the urgency fades, which is exactly when they matter most.
Sources
Every figure on this page traces to one of these. Regulatory documents and
peer-reviewed primary research only — see our editorial policy
for what we accept as a source.
Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. View source
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine. View source
SURMOUNT-4: Weight Reversal Post Tirzepatide Withdrawal. American College of Cardiology journal scan. View source
Wilding JPH et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society, 2021. View source
GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic. View source
Maintenance fails quietly
Food noise, protein and weight trend on one timeline, so drift shows up while it is still small. Core tracking is free.